ABBV receives FDA approval for AbbVie's drug.
AbbVie Inc.（ABBV）的 AbbVie's drug 获美国 FDA 批准。
For information only. Not investment advice.内容仅供参考，不构成投资建议。
Cantor Fitzgerald raises ABBV target to $290Cantor Fitzgerald 上调目标价 艾伯维 (ABBV) 至 $290
Rating Change · October 8, 2026评级变动 · 2026/10/8
Scotiabank raises ABBV target to $320 from $280Scotiabank 上调目标价 艾伯维 (ABBV)：$280 → $320
Rating Change · October 6, 2026评级变动 · 2026/10/6
ABBV receives FDA approval for AbbVie's JUVMO™AbbVie Inc.（ABBV）的 AbbVie's JUVMO™ 获美国 FDA 批准
Material Company Event · September 28, 2026公司公告 · 2026/9/28
